Kayne Anderson Rudnick Investment Management LLC Raises Position in DexCom, Inc. (NASDAQ:DXCM)

Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 70.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 54,310 shares of the medical device company’s stock after acquiring an additional 22,458 shares during the period. Kayne Anderson Rudnick Investment Management LLC’s holdings in DexCom were worth $4,224,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at about $25,000. Private Trust Co. NA lifted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC grew its stake in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter valued at $38,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DXCM stock opened at $66.11 on Tuesday. The firm has a market capitalization of $25.92 billion, a price-to-earnings ratio of 46.23, a PEG ratio of 2.30 and a beta of 1.50. The stock has a fifty day moving average of $74.62 and a 200 day moving average of $76.74. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $139.24. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.00.

Insider Activity

In other news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.32% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.